中国老年患者万古霉素群体药动学及个体化给药应用研究

doi:10.5246/jcps.2020.04.025

中国药学(英文版) ›› 2020, Vol. 29 ›› Issue (4): 260-271.DOI: 10.5246/jcps.2020.04.025

中国老年患者万古霉素群体药动学及个体化给药应用研究

张金^1,2#, 林玮玮^1#, 吴委¹, 郭仙忠¹, 黄品芳¹, 林新华⁴, 焦正^3*, 王长连^1*

1. 福建医科大学附属第一医院药学部, 福建福州 350005
2. 福建医科大学附属协和医院药学部, 福建福州 350001
3. 上海交通大学上海胸科医院药学部, 上海 200030
4. 福建医科大学药学院, 福建福州 350108

收稿日期:2019-12-25 修回日期:2020-02-28 出版日期:2020-04-30 发布日期:2020-03-12
通讯作者: Tel.: +86-591-87981331; +86-21-2220000 ext 3051, E-mail: wcl007@126.com; jiaozhen@online.sh.cn
基金资助:
Guidance Project of Fujian Science and Technology Department (Grant No. 2017Y0033); Fujian Medical Innovation Project (Grant No. 2017-CX-31); Sail Project of Fujian Medical University (Grant No. 2017XQ1068); “Weak Discipline Construction Project” of Shanghai Municipal Commission of Health and Family Planning (Grant No. 2016ZB0301-01).

Population pharmacokinetics of vancomycin in Chinese elderly patients and its application for dose individualisation

Jin Zhang^1,2#, Weiwei Lin^1#, Wei Wu¹, Xianzhong Guo¹, Pinfang Huang¹, Xinhua Lin⁴, Zheng Jiao^3*, Changlian Wang^1*

1. Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian, China
2. Department of Pharmacy, Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian, China
3. Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China
4. The School of Pharmacy, Fujian Medical University, Fuzhou 350108, Fujian, China

Received:2019-12-25 Revised:2020-02-28 Online:2020-04-30 Published:2020-03-12
Contact: Tel.: +86-591-87981331; +86-21-2220000 ext 3051, E-mail: wcl007@126.com; jiaozhen@online.sh.cn
Supported by:
Guidance Project of Fujian Science and Technology Department (Grant No. 2017Y0033); Fujian Medical Innovation Project (Grant No. 2017-CX-31); Sail Project of Fujian Medical University (Grant No. 2017XQ1068); “Weak Discipline Construction Project” of Shanghai Municipal Commission of Health and Family Planning (Grant No. 2016ZB0301-01).

摘要/Abstract

摘要：

本研究旨在构建中国老年患者万古霉素群体药动学(population pharmacokinetics, PPK) 模型, 为中国老年患者提供个体化给药方案。前瞻性收集使用万古霉素的中国老年患者数据, 采用酶联免疫分析法检测万古霉素稳态血药浓度,记录患者性别、年龄、体重、合并用药、感染类型以及实验室检查指标等信息。NONMEM (nonlinear mixed-effects model) 软件构建PPK模型, 蒙特卡洛模拟法设计老年患者的万古霉素初始给药剂量表。研究发现开颅术后脑膜炎与肾小球滤过率是影响万古霉素清除率的主要协变量; 并设计了万古霉素在老年开颅术后脑膜炎及非开颅术后脑膜炎患者中的初始给药剂量推荐表。本研究最终建立了能估算中国老年患者万古霉素个体清除率的PPK模型, 为老年患者万古霉素的个体化给药提供参考。

关键词: 老年患者, 群体药动学, 开颅术后脑膜炎, 万古霉素, 个体化给药

Abstract:

In the present study, we aimed to develop a population pharmacokinetics (PPK) model of vancomycin (VCM) and proposethe individualised dosage regimen for Chinese elderly patients. The data were collected prospectively from Chinese elderly patients receiving VCM therapy. Steady-state trough concentrations of VCM were determined using an enzyme-multiplied immunoassay. Patients’ sex, age, body weight, concomitant medications, infection type, and laboratory findingswere recorded. The PPK model was developed using nonlinear mixed-effects model software. Moreover, we used Monte Carlo simulations to develop an initial dosage regimen targeting various VCM through concentration ranges based on the final model. We found that VCM clearance (CL) was significantly influenced by post-craniotomy meningitis (PCM) and glomerular filtration rate in elderly patients. Additionally, a new dosage regimen was proposed to individualise VCM regimen for PCM and non-PCM elderly patients. A PPK model was established to estimate the individual VCM CL for elderly patients, which could be applied for individualising doses in the target population.

Key words: Elderly patient, Population pharmacokinetics, Post-craniotomy meningitis, Vancomycin, Dose individualisation

中图分类号:

R943

Supporting:

张金, 林玮玮, 吴委, 郭仙忠, 黄品芳, 林新华, 焦正, 王长连. 中国老年患者万古霉素群体药动学及个体化给药应用研究[J]. 中国药学(英文版), 2020, 29(4): 260-271.

Jin Zhang, Weiwei Lin, Wei Wu, Xianzhong Guo, Pinfang Huang, Xinhua Lin, Zheng Jiao, Changlian Wang. Population pharmacokinetics of vancomycin in Chinese elderly patients and its application for dose individualisation[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(4): 260-271.

参考文献

[1] Rybak, M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 2006, 42, S35-S39.

[2] Rybak, M.; Lomaestro, B.; Rotschafer, J.C.; Moellering, R. Jr, Craig, W.; Billeter, M.; Dalovisio, J.R.; Levine, D.P. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am. J. Health-Syst. Pharm. 2009, 66, 82-98.

[3] Matsumoto, K.; Takesue, Y.; Ohmagari, N.; Mochizuki, T.; Mikamo, H.; Seki, M.; Takakura, S.; Tokimatsu, I.; Takahashi, Y.; Kasahara, K.; Okada, K.; Igarashi, M.; Kobayashi, M.; Hamada, Y.; Kimura, M.; Nishi, Y.; Tanigawara, Y.; Kimura, T. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J. Infect. Chemother. 2013, 19, 365-380.

[4] Rodvold, K.A.; Blum, R.A.; Fischer, J.H.; Zokufa, H.Z.; Rotschafer, J.C.; Crossley, K.B.; Riff, L.J. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob. Agents Chemother. 1988, 32, 848-852.

[5] Sánchez, J.L.; Dominguez, A.R.; Lane, J.R.; Anderson, P.O.; Capparelli, E.V.; Cornejo-Bravo, J.M. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int. J. Clin. Pharmacol. Ther. 2010, 48, 525-533.

[6] Guay, D.R.; Vance-Bryan, K.; Gilliland, S.; Rodvold, K.; Rotschafer, J. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J. Clin. Pharmacol. 1993, 33, 918-922.

[7] Bourguignon, L.; Cazaubon, Y.; Debeurme, G.; Loue, C.; Ducher, M.; Goutelle, S. Pharmacokinetics of vancomycin in elderly patients aged over 80 years. Antimicrob. Agents Chemother. 2016, 60, 4563-4567.

[8] Kim, A.J.; Lee, J.Y.; Choi, S.A.; Shin, W.G. Comparison of the pharmacokinetics of vancomycin in neurosurgical and non-neurosurgical patients. Int. J. Antimicrob. Agents. 2016, 48, 381-387.

[9] Lin Wu, F.L.; Liu, S.S.; Yang, T.Y.; Win, M.F.; Lin, S.W.; Huang, C.F.; Wang, K.C.; Shen, L.J. A larger dose of vancomycin is required in adult neurosurgical intensive care unit patients due to augmented clearance. Ther. Drug Monit. 2015, 37, 609-618.

[10] Lin, W.W.; Wu, W.; Jiao, Z.; Lin, R.F.; Jiang, C.Z.; Huang, P.F.; Liu, Y.W.; Wang, C.L. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. Eur. J. Clin. Pharmacol. 2016, 72, 29-37.

[11] Da, L.; Hong, S. A study of drug therapy problems in pharmaceutical care. J. Chin. Pharm. Sci. 2009, 18, 354-357.

[12] Thomson, A.H.; Staatz, C.E.; Tobin, C.M.; Gall, M.; Lovering, A.M. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J. Antimicrob. Chemother. 2009, 63, 1050-1057.

[13] Kullar, R.; Leonard, S.N.; Davis, S.L.; Delgado, G. Jr, Pogue, J.M.; Wahby, K.A.; Falcione, B.; Rybak, M.J. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy. 2011, 31, 441-448.

[14] Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; J Rybak, M.; Talan, D.A.; Chambers, H.F. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 2011, 52, 285-292.

[15] Bautista, J.; Huster, M.; Osterhaus, M. Syva Emit®2000 vancomycin assay. Ther. Drug Monit. 1993, 15, 152.

[16] Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F.III, Feldman, H.I.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Greene, T.; Coresh, J.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009, 150, 604-612.

[17] Glatard, A.; Bourguignon, L.; Jelliffe, R.W.; Maire, P.; Neely, M.N.; Goutelle, S. Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients. Antimicrob. Agents Chemother. 2015, 59, 2986-2994.

[18] Mandema, J.W.; Verotta, D.; Sheiner, L.B. Building population pharmacokinetic: pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm. 1992, 20, 511-528.

[19] Ette, E.I. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 1997, 37, 486-495.

[20] Brendel, K.; Comets, E.; Laffont, C.; Laveille, C.; Mentré, F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm. Res. 2006, 23, 2036-2049.

[21] Comets, E.; Brendel, K.; Mentré, F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput. Methods Programs Biomed. 2008, 90, 154-166.

[22] Lodise, T.P.; Lomaestro, B.; Graves, J.; Drusano, G.L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 2008, 52, 1330-1336.

[23] van der Meer, A.F.; Marcus, M.A.; Touw, D.J.; Proost, J.H.; Neef, C. Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther. Drug Monit. 2011, 33, 133-146.

[24] Bondareva, I.B.; Jelliffe, R.W.; Andreeva, O.V.; Bondareva, K.I. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy. J. Clin. Pharm. Ther. 2011, 36, 625-636.

[25] He, X.R.; Liu, Z.H.; Ji, S.M.; Liu, T.T.; Li, L.; Zhou, T.Y.; Lu, W. Population pharmacokinetics of vancomycin and prediction of pharmacodynamics in the Chinese people. Acta Pharm. Sin. 2014, 49, 1528-1535.

[26] Scaglione, F.; Paraboni, L. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. Int. J. Antimicrob. Agents. 2008, 32, 294-301.

[27] Ott, L.; McClain, C.J.; Gillespie, M.; Young, B. Cytokines and metabolic dysfunction after severe head injury. J. Neurotrauma. 1994, 11, 447-472.

[28] Just, A. Mechanisms of renal blood flow autoregulation: dynamics and contributions. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292, R1-R17.

[29] Jennett, B.; Bond, M. Assessment of outcome after severe brain damage. Lancet. 1975, 1, 480-484.

[30] Sadoh, S.; Tsuji, Y.; Tsukamoto, K. Correlation of pharmacokinetic parameters with serum vancomycin concentration in elderly patients with malignancies. Yakugaku Zasshi. 2010, 130, 69-73.

[31] Teramachi, H.; Hatakeyama, H.; Matsushita, R.; Imai, Y.; Miyamoto, K.; Tsuji, A. Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters. Biol. Pharm. Bull. 2002, 25, 1333-1338.

[32] Purwonugroho, T.A.; Chulavatnatol, S.; Preechagoon, Y.; Chindavijak, B.; Malathum, K.; Bunuparadah, P. Population pharmacokinetics of vancomycin in Thai patients. Sci. World J. 2012, 2012, 762649.

[33] Matsushita, K.; Mahmoodi, B.K.; Woodward, M.; Emberson, J.R.; Jafar, T.H.; Jee, S.H.; Polkinghorne, K.R.; Shankar, A.; Smith, D.H.; Tonelli, M.; Warnock, D.G.; Wen, C.P.; Coresh, J.; Gansevoort, R.T.; Hemmelgarn, B.R.; Levey, A.S.; the Chronic Kidney Disease Prognosis Consortium, F. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012, 307, 1941-1951.

[34] David-Neto, E.; Triboni, A.H.; Ramos, F.; Agena, F.; Galante, N.Z.; Altona, M.; Lemos, F.B.; Sapienza, M.T.; Nahas, W.C. Evaluation of MDRD4, CKD-EPI, BIS-1, and modified Cockcroft-Gault equations to estimate glomerular filtration rate in the elderly renal-transplanted recipients. Clin. Transplant. 2016, 30, 1558-1563.

[35] Cartet-Farnier, E.; Goutelle-Audibert, L.; Maire, P.; De la Gastine, B.; Goutelle, S. Implications of using the MDRD or CKD-EPI equation instead of the Cockcroft-Gault equation for estimating renal function and drug dosage adjustment in elderly patients. Fundam. Clin. Pharmacol. 2017, 31, 110-119.

[36] Park, S.Y.; Lee, K.W. Renal assessment using CKD-EPI equation is useful as an early predictor of contrast- induced nephropathy in elderly patients with cancer. J. Geriatr. Oncol. 2017, 8, 44-49.

[37] Staatz, C.E.; Byrne, C.; Thomson, A.H. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. Br. J. Clin. Pharmacol. 2006, 61, 164-176.

[38] Tanaka, A.; Aiba, T.; Otsuka, T.; Suemaru, K.; Nishimiya, T.; Inoue, T.; Murase, M.; Kurosaki, Y.; Araki, H. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob. Agents Chemother. 2010, 54, 778-782.

[39] Revilla, N.; Martín-Suárez, A.; Pérez, M.P.; González, F.M.; del Mar Fernández de Gatta, M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br. J. Clin. Pharmacol. 2010, 70, 201-212.

[40] Chung, J.Y.; Jin, S.J.; Yoon, J.H.; Song, Y.G. Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J. Korean Med. Sci. 2013, 28, 48-54.

[41] Holford, N.H.; Buclin, T. Safe and effective variability-a criterion for dose individualization. Ther. Drug Monit. 2012, 34, 565-568.

中国老年患者万古霉素群体药动学及个体化给药应用研究

Population pharmacokinetics of vancomycin in Chinese elderly patients and its application for dose individualisation

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价

[1]	冯书云, 陈朋举, 王宁, 赵博, 卢奕帆, 张永恒. 老年慢性病患者合作药物治疗管理模式的探索[J]. 中国药学(英文版), 2022, 31(11): 866-876.
[2]	武海艳, 王涛, 王倩, 唐琳. 新生儿无乳链球菌脑膜炎的抗感染治疗方案分析及停药指征探讨[J]. 中国药学(英文版), 2021, 30(8): 686-691.
[3]	吴朝晖, 林慧芬, 林玮玮, 刘亦伟, 游翔, 林翠鸿, 林荣芳, 曾大勇, 黄品芳. 中国成人万古霉素稳态谷浓度与疗效和安全性相关性的前瞻性队列研究[J]. 中国药学(英文版), 2020, 29(5): 341-354.
[4]	张金莲, 周佳, 陈霁晖, 陈婷, 刘艳, 田怀平, 张健. 临床药师对婴幼儿万古霉素血药浓度监测情况分析[J]. 中国药学(英文版), 2015, 24(4): 263-266.
[5]	叶志康, 唐惠林, 段京莉, 翟所迪^*. 非达霉素与万古霉素治疗艰难梭菌感染的有效性和安全性比较: 系统评价和荟萃分析[J]. 中国药学(英文版), 2013, 22(6): 508-515.
[6]	张扬, 周颖, 张相林, 刘晓, 崔一民, 卢炜^*. 治疗药物监测中基于群体药动学模型设计采样方案的仿真研究[J]. , 2007, 16(4): 241-251.